A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO
暂无分享,去创建一个
N. Rahman | A. Howell | D. Eccles | D. Evans | A. Shenton | F. Lalloo | M. Bulman | E. Amir | K. Young | A. Howell | D. Evans | D. Evans | D. Evans
[1] D. Easton,et al. High Prevalence of the 999 del 5 Mutation in Icelandic Breast and Ovarian Cancer Patients 1 , 2006 .
[2] D. Evans,et al. High detection rate for BRCA2 mutations in male breast cancer families from North West England , 2004, Familial Cancer.
[3] D. Evans,et al. Sensitivity of BRCA1/2 mutation testing in 466 breast/ovarian cancer families , 2003, Journal of medical genetics.
[4] J. Godino,et al. Pre-test prediction models of BRCA1 or BRCA2 mutation in breast/ovarian families attending familial cancer clinics , 2003, Journal of medical genetics.
[5] P. Pharoah,et al. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history , 2003, The Lancet.
[6] B. Weber,et al. Application of breast cancer risk prediction models in clinical practice. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] G. Lenoir,et al. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. , 2002, Journal of the National Cancer Institute.
[8] J. Benítez,et al. Clustering of cancer‐related mutations in a subset of BRCA1 alleles: A study in the Spanish population , 2002, International journal of cancer.
[9] Giovanni Parmigiani,et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. J. van de Vijver,et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Sean V Tavtigian,et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Barbara L. Smith,et al. Model‐based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center , 2002, Cancer.
[13] N E Day,et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes , 2002, British Journal of Cancer.
[14] Douglas F Easton,et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer , 2001, Breast Cancer Research.
[15] Å. Borg,et al. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. , 2001, Journal of the National Cancer Institute.
[16] H. Nevanlinna,et al. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families , 2001, British Journal of Cancer.
[17] D. Evans,et al. 2157delG: a frequent mutation in BRCA2 missed by PTT , 2000, Journal of medical genetics.
[18] A. Whittemore,et al. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. , 2000, Human pathology.
[19] N. Carson,et al. A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center , 2000, Clinical genetics.
[20] C. Mathew,et al. Low prevalence of germlineBRCA1 mutations in early onset breast cancer without a family history , 2000, Journal of medical genetics.
[21] M. Beckmann,et al. The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. , 2000, American journal of human genetics.
[22] S. Seal,et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.
[23] Nazneen,et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. , 1999, Journal of the National Cancer Institute.
[24] H. Olsson. Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.
[25] S. Cummings,et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] I. Campbell,et al. BRCA1 mutations in southern England. , 1998, British Journal of Cancer.
[27] J Chang-Claude,et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.
[28] A. Howell,et al. An evaluation of common breast cancer gene mutations in a population of Ashkenazi Jews. , 1998, Journal of medical genetics.
[29] D. Berry,et al. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.
[30] T. L. McGee,et al. Evidence that the penetrance of mutations at the RP11 locus causing dominant retinitis pigmentosa is influenced by a gene linked to the homologous RP11 allele. , 1997, American journal of human genetics.
[31] K Offit,et al. BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. , 1997, JAMA.
[32] A. Bowcock,et al. Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. , 1997, The New England journal of medicine.
[33] F. Couch,et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.
[34] M. King,et al. Population genetics of BRCA1 and BRCA2. , 1997, American journal of human genetics.
[35] B. Weber,et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. , 1997, American journal of human genetics.
[36] D. Easton,et al. High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. , 1996, Cancer research.
[37] J. D. Thompson,et al. BRCA1 mutations in a population-based sample of young women with breast cancer. , 1996, The New England journal of medicine.
[38] Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] D J Prockop,et al. Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[40] C. Szabó. Medical genetics : advances in brief Population genetics of BRCA 1 and BRCA 2 , 2022 .